Endoscopic Retrograde Cholangiopancreatography Market Growth Insights

1
Biliary Sphincterotomy Retains 45 Share of
Endoscopic Retrograde Cholangiopancreatography
Market
2
In 2021, the endoscopic retrograde
cholangiopancreatography market valued at
1,270.9 million, and it is expected to grow at a
rate of 8.1 from 2021 to 2030, to hit the
2,557.7 million value by 2030. It is attributed
to the growing prevalence of pancreatic disorders
in the geriatric population and the increased
adoption of minimally invasive procedures. The
rise in medical reimbursements is also driving
the market. For example, the average cost of an
endoscopy procedure is more than 3,000 in the
U.S., but due to health insurance, there can be a
reduction of 1,500 in the cost. The
most-significant revenue generator in the
endoscopic retrograde cholangiopancreatography
market is endotherapy devices, holding 40 market
share. It is ascribed to the growing prevalence
of pancreatic disorders such as pancreatitis,
gallbladder stones, pancreatic cancer and
choledocholithiasis, resulting in rising demand
for ERCP devices. According to American Health
Organization, the number of people with
pancreatic cancer is expected to rise to over
60,000 in 2022 in the U.S., with an estimated
forecast of 50,000 deaths from it.
3
Under the application segment, the biliary
sphincterotomy captured the largest revenue
share, amounting to 45 of the endoscopic
retrograde cholangiopancreatography market. It is
attributed to the massive usage of the ERCP
devices in pancreatic disorder treatment
procedures such as common bile duct stones, stent
placement, bile obstruction and tissue sampling.
On average, 10 out of 100,000 men and women are
expected to suffer from intrahepatic bile duct
cancer in the U.S., which signifies the increased
demand for ERCP devices in the region. Under
the end-user segment, hospitals and clinics
contribute significantly to the endoscopic
retrograde cholangiopancreatography market. It is
attributed to the rise in hospitals with trained
and certified endoscopy professionals such as
surgeons and gastroenterologists, resulting in
the mass interventions of endoscopic diagnosis
performed in these facilities. The hospitals and
clinics also offer surgical care, including
diagnostic and preventive procedures, leading to
the proliferation of the market. To receive
free sample pages of this report_at_
https//www.psmarketresearch.com/market-analysis/e
ndoscopic-retrograde-cholangiopancreatography-ercp
-market/report-sample
4
North America contributed 471.4 million in
revenue to the endoscopic retrograde
cholangiopancreatography market last year,
attributed to the growing prevalence of
pancreatic cancer and the increase in number of
deaths caused due to it in the region. Around 3
of deaths are caused due to pancreatic cancer
every year in the U.S. The rise in alcohol
consumption is also the leading cause of several
pancreatic diseases such as PanNET and pancreatic
adenocarcinoma. APAC is expected to witness the
fastest growth in the endoscopic retrograde
cholangiopancreatography market. It is attributed
to the growing prevalence of pancreatic cancer
and GERD, and increased patient awareness of ERCP
devices. The government initiatives to raise
awareness toward pancreatic diseases such as bile
duct cancer, pancreatic conditions and other
complications are also driving the market. China
and Japan collectively hold the 60 share of the
APAC market. Around 3,00,000 deaths are reported
due to GI-related cancers in China, according to
the countrys government organization data.
Therefore, the growing prevalence of pancreatic
diseases and increased death rate due to
pancreatic cancer drive the demand for ERCP
devices, resulting in a market boom. Inquire
before purchase_at_ https//www.psmarketresearch.com/
send-enquiry?enquiry-urlendoscopic-retrograde-cho
langiopancreatography-ercp-market
5
Disclaimer PS Intelligence always keeps its
customers interests at the core while carrying
out research activities. PS Intelligence ensures
the reliability and accuracy of information and
data provided in its market research
publications. However, the information in
publications is subject to fluctuations, as it is
based on primary interviews of officials from
various companies or organizations. PS
Intelligence is not responsible for any incorrect
data provided by the key industry players of the
concerned domain. the information or analysis in
PS Intelligence publications represents opinions
based on research and should not be interpreted
as statements of fact. Information in this report
was believed to be correct at the time of
publication, but cannot be guaranteed. PS
Intelligence does not endorse any product,
service, or vendor depicted in its research
publications. All intellectual properties,
including trademarks and copyrights, belong to
their respective owners and may be protected by
copyright. Under no circumstance can these be
reproduced in any form without prior written
agreement of their owners. An order for market
research report is intended for internal use of
the company only and not for disclosure to third
parties or any other publication in general. No
service, report, or part thereof provided by PS
Intelligence can be reproduced, republished,
resold, revealed, distributed, circulated, or
sublicensed in any medium or form now realized or
hereafter become realized, including but not
limited to, all forms of optical-based media,
magnetic, electronic, or digital, without a
written permission from Prescient Strategic
Intelligence Pvt. Ltd.